Abiomed Receives Approval for Expanded FDA Indication for Cardiomyopathy with Cardiogenic Shock
14 February 2018
Abiomed, Inc., a leading provider of breakthrough heart support and recovery technologies, announced today that it has received an expanded U.S. Food and Drug Administr
